Oncotargets and Therapy for Cancer

Some of Oncotarget articles on cancer focuses on strategies of pro-oncogenic cell signaling devices to address issues of human malignancies. This focus on a particular cancer cell may have identified both gene and drug therapy methods that can be used in treatment and prevention. The medical journal focuses on providing comprehensive information about the translational strategy that fights oncolytic infections. Check Oncotarget at scimagojr.com

Pro-oncogenic signals are the pathway that generates cancer in humans. The development of mutant versions of HSV-1 is a significant milestone in Oncolytic microbes research. The Ras-Smart virus is known as “ Signal Smart 1”. SS1 mutant is a different model of Oncolytic microbes that is designed to attack Cancer Stem Cells (CSCs) on tissue in a particular way.

HSV-1 and SS1 viruses are designed to remove all cancer stem cells that may have tumors. The CSC is a class of cells that can repopulate tumors and support different varieties of cells which make up the histological structures of cancer. No other therapy can efficiently eliminate CSCs in the body. The use of Oncolytic microbes is the best cancer therapy to prevent repopulating tumors in humans.

Listen: https://itunes.apple.com/us/podcast/oncotarget/id1294363732?mt=2

Most of the tumor antigens are known to be “self –antigens” making anti-tumor immune reactions face some inherent problems. Anti-cancer T cells prevent the formation of protective anti-cancer immunity. CD4 T cell can be used by doctors to facilitate the creation of specific reaction of antigen CD8+ cytolytic T lymphocyte (CTL).

Other approaches that can be used to restrict CSCs cells from multiplying include, generation of immunogenic DC that make inhibitory molecules such as IL-10; HSV-VP22 and carrier protein for simultaneous production of CD8 T and CD4 T cell response; utilization of “self-translatable.” The formation of specific donor customized MHC class 1 controlled anti-tumor CD8+ CTL and CD4+ “multifunctional” T cells by creating human peripheral blood obtained from T cells with an MHC class 1 prevented transgenic T cell receptor( TCR), separated from melanoma patient-derived CD8 + CTL.

Onctotarget researchers have consistently sought to produce valuable information regarding cancer treatment and biological processes. Their continued hard work provides options for patients and paves the way to the future of oncology treatments. Learn more at Research Gate.

Dr. Clay Siegall: Bringing Technology and Nature Together In an Attempt to Fight Cancer

Dr. Clay Siegall, the founder and CEO of Seattle Genetics, is a seasoned scientist who has made a substantial contribution in regards to targeted cancer therapies. Through Seattle Genetics, he has brought professional researchers together in an attempt to improve cancer research and to develop more drugs that will satisfactorily address the cancer problem. Siegall holds the belief that the traditional therapies such as chemotherapy do not have a place in the future; scientists must strive to come up with more patient-friendly therapies which are both tolerable and effective. Inspirery.com managed to have a word with the legend and shared his story with its readers.

The Interview

Nature has a way of eradicating the disease. With a little help from technology, nature can change the fate of people who suffer from chronic diseases and whose chances of survival are minimal by making them full of life once more. That knowledge is what motivated Dr. Siegall to start Seattle Genetics. The closest he had got to a cancer patient was when a close relative was diagnosed with the disease. By then, Siegall was a student at the University of Maryland. Although he didn’t have the necessary expertise on cancer treatment, he was not convinced that chemo, amputation, and radical surgery were the best treatment that a patient could get.

After establishing the company in 1998, Clay Siegall had to struggle to maintain it in operation. He told Inspirery.com that the situation had gone to the extremes to the point that he had contemplated about closing down the firm. He was able to work through, and in a decade’s time, Seattle Genetics started making huge profits. He attributed his success to his team of researchers, talented salespeople, and other staff members who fully understand the business of the company and its goals. The unique products that the company develops have also gone a long way in growing his trade.

About Siegall

Before joining George Washington University for his Ph.D. in genetics, Dr. Clay Siegall had already graduated from revered The University of Maryland with a degree in Zoology. His post-doctoral research has given birth to several FDA-approved anti-cancer therapies.

Besides his prowess in science, Siegall is good at business management. In 2001, he led Seattle Genetics in a financing round that yielded more than $675 million. Siegall has also worked with Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 until he left to pursue entrepreneurship.